BPC-157: A Comprehensive Review of Current Research

Introduction

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of a protein found in human gastric juice. First isolated and characterized by researchers at the University of Zagreb in the early 1990s, BPC-157 consists of 15 amino acids and has since become one of the most extensively studied peptides in preclinical biology.

What makes BPC-157 particularly noteworthy to the research community is its unusual stability. Unlike most peptides, it remains biologically intact in highly acidic environments—a quality that has made it a subject of considerable interest across multiple fields. Over 190 indexed publications now reference BPC-157, with the majority produced by the laboratory of Dr. Predrag Sikiric at Zagreb University School of Medicine, who has served as the primary investigator across decades of preclinical work. Studies have examined the compound across a broad range of biological systems, from gastrointestinal mucosa and musculoskeletal tissue to the central nervous system and vascular endothelium.

Molecular Profile

BPC-157 carries the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (single-letter code: GEPPPGKPADDAGLV). Its molecular formula is C₆₂H₉₈N₁₆O₂₂, with a molecular weight of approximately 1,419.56 Da.

One of the compound’s defining characteristics is its resistance to proteolytic degradation. Research has shown that BPC-157 remains stable in human gastric juice for more than 24 hours under simulated conditions—an unusual property for a peptide of its size. This stability has made it a practical subject for oral, intraperitoneal, and local administration models in rodent studies. For laboratory use, the compound is typically supplied as a lyophilized (freeze-dried) white powder.

Key Research Areas

1. Gastrointestinal Research

The earliest and most extensive body of BPC-157 research focuses on the gastrointestinal tract. In a landmark 1994 study, Sikiric P., Seiwerth S., Grabarevic Z., et al. published findings in Life Sciences demonstrating that BPC-157 significantly attenuated gastric and duodenal lesions in rat models exposed to restraint stress, cysteamine, and 96% ethanol. Compared against H2 receptor antagonists and other reference compounds, BPC-157 produced consistent cytoprotective effects across multiple injury models.

Subsequent work expanded these findings to intestinal anastomosis models. A review published in Pharmaceuticals (2024) summarized decades of rat-model data showing that the peptide influenced healing of surgically created intestinal anastomoses, with animals receiving BPC-157 exhibiting improved tissue organization and anastomotic strength compared to controls.

The gastrointestinal cytoprotection hypothesis—now referred to by Sikiric’s team as “organoprotection”—has been revisited in a 2020 paper in Gut and Liver, where the authors proposed that BPC-157’s effects extend beyond localized mucosal protection to broader systemic responses to physiological stress.

2. Musculoskeletal and Tendon Research

BPC-157 has been extensively studied in rodent models of tendon and ligament injury, making musculoskeletal biology one of its most cited research domains.

Staresinic M., Sebecic B., Patrlj L., et al. published a pivotal study in the Journal of Orthopaedic Research (2003) demonstrating that BPC-157 accelerated healing of transected rat Achilles tendons and, in parallel in vitro work, stimulated tendocyte growth while reversing the growth-inhibiting effects of the aldehyde 4-hydroxynonenal (HNE).

A subsequent study by Krivic A., Majerovic M., Jelic I., Seiwerth S., Sikiric P. published in the Journal of Orthopaedic Research (2006) examined Achilles tendon-to-bone healing—a model that does not resolve spontaneously in rats. Animals treated with BPC-157 showed improved Achilles Functional Index (AFI) scores, increased load-to-failure values, enhanced collagen fiber organization, and more advanced vascular formation compared to saline controls.

A 2010 study by Cerovecki T. et al. in the Journal of Orthopaedic Research extended these findings to medial collateral ligament (MCL) models, reporting improved ligament continuity and tissue architecture in BPC-157-treated rats at multiple timepoints post-injury.

A 2025 systematic review by Vasireddi N., Hahamyan H., Salata M.J., et al. published in a Sage Journals orthopaedic sports medicine publication synthesized the existing animal literature, concluding that preclinical evidence consistently points toward improved structural healing outcomes in tendon and ligament injury models, while emphasizing the absence of human clinical trial data.

3. Neuroprotective Research

Preclinical investigations have begun to characterize BPC-157 activity within the central and peripheral nervous systems. Sikiric P., Seiwerth S., Rucman R., et al. published a comprehensive review in Current Neuropharmacology (2016, Vol. 14, No. 8, pp. 857–865) examining the brain-gut axis relationship and BPC-157’s apparent modulatory effects on serotonergic and dopaminergic signaling in rodent models.

Studies have demonstrated neuroprotective activity in several specific rat models: somatosensory neuron protection following chemical challenge; apparent peripheral nerve regeneration following transection injury; and attenuation of lesion progression in traumatic brain injury models. The 2022 review article “Pentadecapeptide BPC 157 and the Central Nervous System,” published in Neural Regeneration Research, further detailed rat studies in which BPC-157 administration counteracted cerebral ischemia/reperfusion injury induced by bilateral carotid artery clamping, with animals showing improved memory, locomotion, and coordination outcomes versus controls.

4. Vascular and Angiogenesis Research

Research into BPC-157’s effects on vascular biology has produced some of the most mechanistically detailed findings in the field. Brcic L., Brcic I., Staresinic M., Novinscak T., Sikiric P., Seiwerth S. published findings in Journal of Physiology and Pharmacology (2009, Suppl. 7, pp. 191–196) demonstrating that BPC-157 exerted a modulatory influence on angiogenesis during muscle and tendon healing in rat models, with enhanced VEGF-associated vascular formation observed histologically.

A later mechanistic study published in the Journal of Molecular Medicine (2016) by Chang C.H. and colleagues reported that BPC-157 promoted angiogenesis in chorioallantoic membrane (CAM) assays and in vitro tube formation assays, and accelerated blood flow recovery in a rat hindlimb ischemia model. The authors identified upregulation of VEGFR2 expression as a potential mechanistic correlate, making this one of the more granular receptor-level investigations to date.

Mechanisms of Action Under Investigation

The molecular mechanisms underlying BPC-157’s observed preclinical effects remain an active area of investigation. Researchers have proposed several non-exclusive explanatory frameworks.

One prominent hypothesis centers on the peptide’s apparent interaction with growth factor receptor signaling. In endothelial cell cultures, BPC-157 has been observed to activate ERK1/2 signaling cascades, with downstream effects on transcription factors including c-Fos, c-Jun, and Egr-1—proteins associated with cell proliferation and migration.

A second line of inquiry focuses on BPC-157’s relationship with the nitric oxide (NO) system. Multiple preclinical studies suggest the compound modulates NO-mediated vascular responses, though researchers note that the direction of this effect appears context-dependent: the peptide has been observed to both support and counteract NO activity depending on the injury model studied.

Researchers have also described what Sikiric’s group terms an “organoprotective” effect—a generalized cytoprotective response that appears to extend across tissue types in rodent models. The precise molecular basis of this broad-spectrum activity is not yet established, and current investigations are examining receptor binding profiles, gene expression changes in healing tissue, and interactions with the autonomic nervous system. No lethal dose (LD₅₀) has been determined in rodent studies, which researchers note as a relevant safety parameter for continued preclinical evaluation.

Research Considerations for Laboratory Use

For investigators working with BPC-157 in laboratory settings, several practical characteristics are relevant. The compound is most stable as a lyophilized powder and should be stored at −20°C or below prior to reconstitution. Reconstituted solutions are generally prepared in sterile bacteriostatic water or 0.9% saline for in vivo administration, and should be used within 24–48 hours of preparation when refrigerated.

BPC-157 is water-soluble and does not require carrier solvents such as DMSO for aqueous preparation. Research-grade material is typically characterized by HPLC purity of ≥98% and confirmed by mass spectrometry to verify the molecular weight of 1,419.56 Da. Lot-specific certificates of analysis (CoAs) are standard practice for research procurement and should include identity, purity, and sterility data.

Conclusion

BPC-157 occupies a genuinely unusual position in peptide research: a compound with a growing body of preclinical evidence spanning multiple biological domains, yet one for which human clinical trial data remains limited. The preponderance of published work originates from a single research group, and independent replication—while emerging—is still limited. Nonetheless, the breadth of preclinical findings across gastrointestinal, musculoskeletal, neurological, and vascular models has attracted sustained interest from the broader scientific community.

As with any compound at this stage of investigation, conclusions about mechanism, efficacy, and safety in human systems remain premature. Researchers interested in BPC-157 as a laboratory tool should engage with the primary literature critically and design experiments with appropriate controls and validated end points.

Frequently Asked Questions

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a partial sequence of a protein found in human gastric juice. It was first characterized by researchers at the University of Zagreb in the early 1990s and has since been the subject of more than 190 indexed preclinical publications. It is not approved by the FDA for human use and is produced for research purposes only.

What research has been conducted on BPC-157?

The majority of published research on BPC-157 consists of preclinical studies conducted in rodent models. Key research areas include gastrointestinal cytoprotection, tendon and ligament healing, neuroprotection in traumatic injury and ischemia models, and vascular angiogenesis. Primary researchers include Dr. Predrag Sikiric and Dr. Sven Seiwerth at the University of Zagreb, with contributions from independent groups increasingly appearing in the literature. Human clinical trials are limited.

How is BPC-157 used in research settings?

In published preclinical studies, BPC-157 has been administered via multiple routes—intraperitoneal injection, oral gavage, intramuscular injection, and topical application—depending on the biological system under study. Route of administration and concentration vary considerably across published protocols. Researchers working with the compound should consult primary literature for model-specific parameters and obtain material with verified purity and identity documentation.

What is the purity standard for research-grade BPC-157?

Research-grade BPC-157 is typically characterized at ≥98% purity by HPLC analysis, with identity confirmed by mass spectrometry (expected molecular weight: 1,419.56 Da). Reputable suppliers provide lot-specific certificates of analysis documenting purity, water content, residual solvents, and sterility. These documents are an essential part of any reproducible research protocol using synthetic peptides.

References

1. Sikiric P, Seiwerth S, Grabarevic Z, et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. Life Sciences. 1994;54(5):PL63–PL68. PMID: 7904712.
2. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976–983. PMID: 14554208.
3. Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5):982–989. PMID: 16583442.
4. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology. 2009;60(Suppl 7):191–196. PMID: 20388964.
5. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology. 2016;14(8):857–865. PMID: 27138887.
6. Hsieh MJ, Tsai WC, Hsu YH, Pang JH. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323–333. PMID: 27847966.
7. Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology. 2021;12:627533. PMID: 34267654.
8. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Sports Health. 2025. PMID: 40756949.
9. Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals. 2025;18(2):185. PMID: 40005999.

BPC-157 is supplied by Rejuven8 Peptides for in vitro and in vivo laboratory research use only. It is not approved for human or veterinary use.

Explore our lab-tested BPC-157 → /product/bpc-157

Browse Our Lab-Tested Research Peptides →

All products are sold for research purposes only. Not for human consumption.